Zepbound contains tirzepatide. It is approved for weight management in qualifying adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Its approved uses differ from Mounjaro’s, although both contain tirzepatide.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | tirzepatide |
| Medicine class | GIP / GLP-1 receptor agonist |
| Forms and strengths | Weekly injection: 2.5, 5, 7.5, 10, 12.5 and 15 mg; single-dose and multidose presentations |
Approved uses in adults
Zepbound is approved alongside a reduced-calorie diet and increased physical activity for weight reduction and long-term maintenance in adults with obesity, or overweight with at least one weight-related condition. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.
Source: [1]
Weekly strengths and presentations
The six strengths range from 2.5 to 15 mg. Current labeling includes single-dose pens and vials and multidose presentations, including a four-dose KwikPen. Dose volume and device instructions vary. Starting and maintenance doses serve different purposes and should not be inferred from a list of pack strengths. For more on starting and maintenance schedules, read the Tirzepatide Dosing guide.
Source: [1]
The boxed warning
Tirzepatide caused thyroid C-cell tumors in rats; whether it causes these tumors in humans is unknown. Zepbound must not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).
Source: [1]
Other precautions and planning
Pancreatitis, severe gastrointestinal effects, gallbladder disease and dehydration-related kidney injury are important concerns. The label advises additional or non-oral contraception for four weeks after starting and after each dose increase when oral hormonal contraception is used. Pregnancy plans and procedures need discussion with the clinical team.
Source: [1]
Zepbound and Mounjaro
Mounjaro also contains tirzepatide, but has different approved uses. Zepbound is not a generic version of Mounjaro, and using them together is not recommended. A clinician should provide a new prescription and product-specific directions for any change between them.
Source: [1]
Questions and answers
Does Zepbound’s sleep-apnea use apply to everyone with sleep apnea?
No. The label specifies adults with obesity and moderate-to-severe obstructive sleep apnea.
Is Zepbound a generic Mounjaro?
No. They share tirzepatide but are distinct branded products with different approved uses.
Does every Zepbound pen contain one dose?
No. Current labeling also includes a four-dose KwikPen.
Related reading
Sources
Sources checked 1 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026